← Evidence map

ArticleInvestigational new drugs2021

Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma.

Frank Kroschinsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma. | OpenQuestion